TickerFacts.

Scilex Holding Co (SCLX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$341.38M
Year ended 2025-12-31
-$350.88M
Trailing 12 months to 2026-06-30
2020-12-31: -$31.48M2021-12-31: -$32.06M2022-12-31: -$46.67M2023-12-31: -$101.28M2024-12-31: -$79.35M2025-12-31: -$341.38M-$341.38M
2020-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$341.38Mn/m2026-04-10, From 2025-01-01
2024-12-31-$79.35Mn/m2026-04-10, From 2024-01-01
2023-12-31-$101.28Mn/m2025-03-31, From 2023-01-01
2022-12-31-$46.67Mn/m2024-03-12, From 2022-01-01
2021-12-31-$32.06Mn/m2024-03-12, From 2021-01-01
2020-12-31-$31.48Mn/a2023-03-07, From 2020-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Scilex Holding Co (SCLX)2025-12-31-$341.38Mn/m
Precision Biosciences Inc (DTIL)2025-12-31-$50.68Mn/m
X4 Pharmaceuticals, Inc (XFOR)2025-12-31-$85.61Mn/m
C4 Therapeutics, Inc. (CCCC)2025-12-31-$113.26Mn/m
Kymera Therapeutics, Inc. (KYMR)2025-12-31-$341.09Mn/m
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31-$117.28Mn/m
Alector, Inc. (ALEC)2025-12-31-$150.29Mn/m
LENZ Therapeutics, Inc. (LENZ)2025-12-31-$90.85Mn/m
Champions Oncology, Inc. (CSBR)2026-04-30$237.0K-96.2%

Compare SCLX, DTIL, XFOR, CCCC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗